The EEF1A1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HeLa cells with targeted disruption of the EEF1A1 gene. This loss-of-function model enables investigation of EEF1A1 roles in translation elongation, cytoskeletal organization, and apoptosis without clonal bias. The polyclonal format provides a heterogeneous gene-edited pool suitable for robust functional studies in a widely used cancer cell line.
HeLa cells originate from an HPV18-positive cervical adenocarcinoma of a 31-year-old African American woman. These rapidly proliferating epithelial cells serve as a principal model for cancer biology, cell signaling, and HPV-mediated transformation. Their robust growth and genetic tractability make them ideal for CRISPR-based knockout, allowing dissection of EEF1A1 contributions to cervical carcinoma phenotypes.
EEF1A1 is a GTP-dependent elongation factor delivering aminoacyl-tRNA to the ribosomal A-site, a central step in protein synthesis. It also bundles actin, coupling translation to cytoskeletal dynamics. Upstream signals from mTOR, PI3K-Akt, and MAPK pathways, triggered by insulin, EGF, and serum, regulate EEF1A1 activity. It interacts with EEF1B2, EEF1G, ribosomal subunits, and aminoacyl-tRNA synthetases. Knockout reduces global protein synthesis, disrupts actin organization, and sensitizes cells to apoptosis, partly via impaired mTOR-RPS6KB1-EIF4E signaling and Rho GTPase-dependent cytoskeletal regulation.
HeLa cells demand high translational output and actin remodeling; thus, EEF1A1 disruption creates a critical vulnerability. This model is valuable for studying HPV-positive cervical cancer, where EEF1A1 overexpression may support malignant growth. Loss of EEF1A1 can impair proliferation, migration, and survival, while also providing insights into related cancers (breast, lung) and neurodegeneration. The polyclonal knockout facilitates examination of pathway adaptations and therapeutic responses.
Typical applications include polysome and ribosome profiling for translation analysis, Western blotting, RT-qPCR, and co-immunoprecipitation to assess protein expression and interactions. Actin cytoskeleton staining, immunofluorescence, and functional assays (annexin V, MTT, flow cytometry) enable phenotypic characterization. This model supports studies of drug resistance, mTOR and PI3K-Akt pathway dependencies, and the intersections between translation and cytoskeletal regulation. For further details, please contact Ascent Research.
